Categories Cancer Treatment

Update: FDA in the News: FDA approvals and health information on breast cancer

This XRAY review reports new treatments approved by the FDA for early and metastatic breast cancer and educational resources about women's health. (Posted 8/4/25)

Study: FDA approves new targeted therapy for advanced pancreatic cancer

A new treatment called Bizengri has been approved by the FDA for patients with advanced or metastatic pancreatic cancer. This treatment targets pancreatic cancer or non-small cell lung cancers that have a rare tumor mutation called an NRG1 fusion. (Posted 7/24/25)

Study: New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers

About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)

Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer

Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)

Study: Two immunotherapy drugs are better than one for some metastatic colorectal cancers

Combining two immunotherapy drugs is a more effective treatment for certain metastatic colorectal cancers than using either treatment drug alone. Used together, Opdivo (nivolumab) plus Yervoy (ipilimumab) slowed cancer growth in MSI-High metastatic colorectal cancers, a type of colorectal cancer often found in Lynch syndrome. The FDA approved this combined treatment for MSI-High metastatic colorectal cancer after progression with chemotherapy. (Posted 4/30/25)

Este artículo está disponible en español

Update: News from the FDA: Colorectal cancer screening and treatment

This XRAY review is a summary of FDA colorectal cancer (CRC) updates in the last year, including education regarding CRC screening, three treatment drugs targeting different types of CRC and two colorectal screening tests. (Posted 4/16/25)

Este artículo está disponible en español

Update: Ovarian suppression may reduce breast cancer recurrence

Ovarian suppression—blocking estrogen production in the ovaries—can improve breast cancer outcomes in premenopausal women. This review provides information about ovarian suppression and describes who might benefit. (Posted 3/6/25)

Este artículo está disponible en español.

Topic: Addressing the needs of young adults with breast cancer

This update addresses common concerns faced by young adults with breast cancer, particularly fertility and childbearing, psychosocial health and treatment-related side effects. (Posted 2/28/25)

Este artículo está disponible en español.

Article: Life with a high-risk pancreatic and melanoma cancer mutation

One woman seeks genetic testing after her sister died of pancreatic cancer. Despite how her family’s mutation in the CDKN2A gene resulted in multiple cancer diagnoses and deaths and a suspicious finding during her own pancreatic cancer screening, Amarensia Spruitenburg shares a message of hope and gratitude. By telling her story, Amarensia highlights the impact that hereditary cancer can have on families.  (Posted 11/22/24)

Este artículo está disponible en español.

Update: News from the FDA: New endometrial cancer approvals

The FDA recently approved three new immunotherapy treatments (Jemperli, Imfinzi and Keytruda) for advanced endometrial cancer. (Posted 11/7/24)

Este artículo está disponible en español.